[go: up one dir, main page]

WO2000001718A3 - Ns4a-ns3 catalytic domain of hepatitis c - Google Patents

Ns4a-ns3 catalytic domain of hepatitis c Download PDF

Info

Publication number
WO2000001718A3
WO2000001718A3 PCT/US1999/015035 US9915035W WO0001718A3 WO 2000001718 A3 WO2000001718 A3 WO 2000001718A3 US 9915035 W US9915035 W US 9915035W WO 0001718 A3 WO0001718 A3 WO 0001718A3
Authority
WO
WIPO (PCT)
Prior art keywords
ns4a
hepatitis
polypeptides
catalytic domain
polyprotein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/015035
Other languages
French (fr)
Other versions
WO2000001718A2 (en
Inventor
Ben M Dunn
Marina Bukhtiyarova
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Florida
Original Assignee
University of Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Florida filed Critical University of Florida
Priority to AU48552/99A priority Critical patent/AU4855299A/en
Publication of WO2000001718A2 publication Critical patent/WO2000001718A2/en
Publication of WO2000001718A3 publication Critical patent/WO2000001718A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • C12N9/506—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses derived from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The subject invention concerns modified domains of the polyprotein of the hepatitis C virus. The polypeptides of the invention are directed to modified forms of the NS3 and NS4A domains of the polyprotein. In one embodiment, the NS4A fragment is covalently attached to the NS3 catalytic domain. The NS4A fragment is attached to the N-terminal end of NS3. The subject invention also concerns polynucleotides that encode the NS3/NS4A polypeptides. The invention also pertains to methods of preparing the subject polypeptides and methods for screening for compounds that inhibit the serine protease activity of the NS3 protein.
PCT/US1999/015035 1998-07-02 1999-07-02 Ns4a-ns3 catalytic domain of hepatitis c Ceased WO2000001718A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU48552/99A AU4855299A (en) 1998-07-02 1999-07-02 Ns4a-ns3 catalytic domain of hepatitis c

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9167598P 1998-07-02 1998-07-02
US60/091,675 1998-07-02

Publications (2)

Publication Number Publication Date
WO2000001718A2 WO2000001718A2 (en) 2000-01-13
WO2000001718A3 true WO2000001718A3 (en) 2000-04-20

Family

ID=22229082

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/015035 Ceased WO2000001718A2 (en) 1998-07-02 1999-07-02 Ns4a-ns3 catalytic domain of hepatitis c

Country Status (2)

Country Link
AU (1) AU4855299A (en)
WO (1) WO2000001718A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7491808B2 (en) 2000-06-15 2009-02-17 Novartis Vaccines And Diagnostics, Inc. HCV non-structural protein mutants and uses thereof
US7705138B2 (en) 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
CA2629343A1 (en) * 2005-11-11 2007-05-24 Vertex Pharmaceuticals, Inc. Hepatitis c virus variants

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996036702A2 (en) * 1995-05-12 1996-11-21 Schering Corporation Soluble, active hepatitis c virus protease
WO1997008304A2 (en) * 1995-08-22 1997-03-06 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Methodology to produce, purify and assay polypeptides with the proteolytic activity of the hcv ns3 protease
WO1999028482A2 (en) * 1997-11-28 1999-06-10 Schering Corporation Single-chain recombinant complexes of hepatitis c virus ns3 protease and ns4a cofactor peptide

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996036702A2 (en) * 1995-05-12 1996-11-21 Schering Corporation Soluble, active hepatitis c virus protease
WO1997008304A2 (en) * 1995-08-22 1997-03-06 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Methodology to produce, purify and assay polypeptides with the proteolytic activity of the hcv ns3 protease
WO1999028482A2 (en) * 1997-11-28 1999-06-10 Schering Corporation Single-chain recombinant complexes of hepatitis c virus ns3 protease and ns4a cofactor peptide

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BARTENSCHLAGER R ET AL: "COMPLEX FORMATION BETWEEN THE NS3 SERINE-TYPE PROTEINASE OF THE HEPATITIS C VIRUS AND NS4A AND ITS IMPORTANCE FOR POLYPROTEIN MATURATION", JOURNAL OF VIROLOGY, vol. 69, no. 12, 1 December 1995 (1995-12-01), pages 7519 - 7528, XP002053692 *
DIMASI N ET AL: "Engineering, characterization and phage display of hepatitis C virus NS3 protease and NS4A cofactor peptide as a single-chain protein.", PROTEIN ENGINEERING, (1998 DEC) 11 (12) 1257-65. JOURNAL CODE: PR1. ISSN: 0269-2139., ENGLAND: United Kingdom, XP002103545 *
KIM J L ET AL: "CRYSTAL STRUCTURE OF THE HEPATITIS C VIRUS NS3 PROTEASE DOMAIN COMPLEXED WITH A SYNTHETIC NS4A COFACTOR PEPTIDE", CELL, vol. 87, no. 4, 18 October 1996 (1996-10-18), pages 343 - 355, XP002053693 *
LIN C ET AL: "HEPATITIS C VIRUS NS3 SERINE PROTEINASE: TRANS-CLEAVAGE REQUIREMENTS AND PROCESSING KINETICS", JOURNAL OF VIROLOGY, vol. 68, no. 12, 1 December 1994 (1994-12-01), pages 8147 - 8157, XP002012002 *
TAREMI S S ET AL: "Construction, expression, and characterization of a novel fully activated recombinant single-chain hepatitis C virus protease.", PROTEIN SCIENCE, (1998 OCT) 7 (10) 2143-9. JOURNAL CODE: BNW. ISSN: 0961-8368., United States, XP002103544 *
YAN Y ET AL: "Complex of NS3 protease and NS4 peptide of BK strain hepatitis C virus:", PROTEIN SCIENCE, vol. 7, no. 4, April 1998 (1998-04-01), pages 837 - 847, XP002103543 *

Also Published As

Publication number Publication date
AU4855299A (en) 2000-01-24
WO2000001718A2 (en) 2000-01-13

Similar Documents

Publication Publication Date Title
WO1999038888A3 (en) Peptide inhibitors of the serine protease activity associated to the ns3 protein of hcv, relevant uses and process of production
Wengler et al. In vitro synthesis of West Nile virus proteins indicates that the amino-terminal segment of the NS3 protein contains the active centre of the protease which cleaves the viral polyprotein after multiple basic amino acids
DE69709671D1 (en) INHIBITORS OF SERINE PROTEASES, ESPECIALLY NS3 PROTEASE OF THE HEPATITIS C VIRUS
DE122012000004I1 (en) Peptides as inhibitors of the hepatitis C virus NS3 serine protease.
DK1169339T3 (en) Macrocyclic peptides that inhibit Hepatitis C virus NS3 protease
PT935609E (en) CRYSTALLIZING COMPOSITIONS CONTAINING A COMPLEX BETWEEN THE PROTEASE NS3 DOMAIN OF HEPATITIS C VIRUS AND NS4A RESULTANT CRYSTALS
AU1416099A (en) Single-chain recombinant complexes of hepatitis c virus ns3 protease and ns4a cofactor peptide
DE60036881D1 (en) NEW NON-STRUCTURAL HCV POLYPEPTIDE
WO2000001813A3 (en) Peptide inhibitors of androgen-independent activation of androgen receptor
CA2365262A1 (en) Surrogate cell-based system and method for assaying the activity of hepatitis c virus ns3 protease
SI0932617T1 (en) Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
Yasunori et al. Identification of the domain required for trans-cleavage activity of hepatitis C viral serine proteinase
WO2001021807A8 (en) Hepatitis c virus envelope two protein (e2) which lacks all or part of the hypervariable region one (hvr1), corresponding nucleic acids, chimeric viruses and uses thereof
WO2000001718A3 (en) Ns4a-ns3 catalytic domain of hepatitis c
EP1141255A4 (en) Modified forms of hepatitis c virus ns3 protease
DE69928064D1 (en) MIMOTOPES OF THE HYPERVARIABLE REGION OF THE E2 GLYCOPROTEIN OF HCV AND ITS USES
AU4397097A (en) Soluble polypeptides with activity of the ns3 serine protease of hepatitis c virus, and process for their preparation and isolation
WO2006024020A3 (en) Hcv non-structural protein mutants and uses thereof
Drouet et al. Hepatitis C virus NS3 serine protease interacts with the serpin C1 inhibitor
WO2000024771A3 (en) Nucleic acids encoding osteoprotegerin-like proteins and methods of using same
DK1417233T3 (en) Human recombinant antibody against hepatitis C (HCV) non-structural NS3 protein, nucleic acid and uses thereof
Maruyama et al. Prolylendopeptidase inhibitory activity of a glial fibrillary acidic protein fragment and other proline-rich peptides
GB0006537D0 (en) Assays and screening methods
WO2001072824A3 (en) Apoptin-associating protein
Mori et al. The N-terminal region of NS3 serine proteinase of hepatitis C virus is important to maintain its enzymatic integrity

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AU BA BB BG BR CA CN CU CZ EE GD GE HR HU ID IL IN IS JP KP KR LC LK LR LT LV MG MK MN MX NO NZ PL RO SG SI SK SL TR TT UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AU BA BB BG BR CA CN CU CZ EE GD GE HR HU ID IL IN IS JP KP KR LC LK LR LT LV MG MK MN MX NO NZ PL RO SG SI SK SL TR TT UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

122 Ep: pct application non-entry in european phase